These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 38408390)
1. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates. Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390 [TBL] [Abstract][Full Text] [Related]
2. [Design of next generation antibody drug conjugates]. Zhu GD; Fu YX Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971 [TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862 [TBL] [Abstract][Full Text] [Related]
4. Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates. Gromek SM; Balunas MJ Curr Top Med Chem; 2015; 14(24):2822-34. PubMed ID: 25487009 [TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates: Principles and opportunities. Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384 [TBL] [Abstract][Full Text] [Related]
6. Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Wang YJ; Li YY; Liu XY; Lu XL; Cao X; Jiao BH Mar Drugs; 2017 Jan; 15(1):. PubMed ID: 28098746 [TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates Containing Payloads from Marine Origin. Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497 [TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs? Zhang B; Wang M; Sun L; Liu J; Yin L; Xia M; Zhang L; Liu X; Cheng Y J Med Chem; 2024 Jul; 67(14):11469-11487. PubMed ID: 38980167 [TBL] [Abstract][Full Text] [Related]
9. Payload diversification: a key step in the development of antibody-drug conjugates. Conilh L; Sadilkova L; Viricel W; Dumontet C J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546 [TBL] [Abstract][Full Text] [Related]
13. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates. Yamada K; Ito Y Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187 [TBL] [Abstract][Full Text] [Related]
14. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Chen H; Lin Z; Arnst KE; Miller DD; Li W Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044 [TBL] [Abstract][Full Text] [Related]
16. The Recent Developments of ADCs with the Tubulysins as the Payloads. Xiangrong X; Yao L; Yao A Mini Rev Med Chem; 2023; 23(18):1797-1805. PubMed ID: 36825713 [TBL] [Abstract][Full Text] [Related]
18. Linkers Having a Crucial Role in Antibody-Drug Conjugates. Lu J; Jiang F; Lu A; Zhang G Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329 [TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy. Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981 [TBL] [Abstract][Full Text] [Related]
20. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]